Exact Mass: 559.130139

Exact Mass Matches: 559.130139

Found 15 metabolites which its exact mass value is equals to given mass value 559.130139, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

dTDP-D-desosamine

dTDP-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-D-glucose; dTDP-alpha-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucose; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucopyranose

C18H31N3O13P2 (559.1332056)


   
   

dTDP-beta-L-evernosamine

dTDP-beta-L-evernosamine; dTDP-3-amino-2,3,6-trideoxy-3-C-methyl-4-O-methyl-beta-L-arabino-hexopyranose

C18H31N3O13P2 (559.1332056)


   

dTDP-4-ethylamino-3-O-methyl-2,4-dideoxy-L-threo-pentopyranose

dTDP-4-ethylamino-3-O-methyl-2,4-dideoxy-L-threo-pentopyranose

C18H31N3O13P2 (559.1332056)


   
   
   

Gadoteridol

3-methyl-16,19,24-trioxo-2,17,18,25-tetraoxa-5lambda5,8lambda5,11lambda5,14lambda5-tetraaza-1-gadolinaoctacyclo[9.6.3.3^{1,8}.2^{5,14}.0^{1,5}.0^{1,8}.0^{1,11}.0^{1,14}]pentacosan-2-ium-5,8,11,14-tetrakis(ylium)-1,1-diuide

C17H29GdN4O7 (559.1277253999999)


Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

   
   

Gadoteridol

gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate

C17H29GdN4O7 (559.1277253999999)


V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

   

2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex

2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex

C28H37ClNPPd (559.1386752000001)


   

4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside

4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside

C24H24F3NO11 (559.130139)


   

Galicaftor

Galicaftor

C28H21F4NO7 (559.1254084)


C87006 - Pharmacological Chaperone

   
   

Gadolinium-HP-Do 3A

Gadolinium-HP-Do 3A

C17H29GdN4O7 (559.1277253999999)


V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

   

2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide

2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide

C24H25F4N3O6S (559.1400118)